Table 2.

Immune-related adverse events.

Adverse events, n (%)	Grade 1/2	Grade 3/4	Total
Neoadjuvant phase
Skin toxicity	2 (6.7%)	2 (6.7%)	4 (13.3%)
Interstitial nephritis	2 (6.7%)	2 (6.7%)	4 (13.3%)
Thyrotoxicosis	2 (6.7%)	0	2 (6.7%)
Hypophysitis	1 (3.3%)	0	1 (3.3%)
Elevated transaminitis and bilirubin	0	1 (3.3%)	1 (3.3%)
Elevated amylase and lipase	0	1 (3.3%)	1 (3.3%)
Adjuvant phase
Myocarditis	1(6.25%)	0	1(6.25%)